Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit

Rhea-AI Summary

Market Context

Historical event 1061691 recorded a -2.62% 24-hour reaction to expedited discovery involving alleged...

Analysis

Historical event 1061691 recorded a -2.62% 24-hour reaction to expedited discovery involving alleged naked short-sellers. That precedent frames the current amended complaint; allegations remain unproven, and low short positioning is the sourced risk to monitor.

Key Figures

Named defendants: 10 defendants Failed-to-deliver shares: 29.6 million shares Outstanding-share failures: More than 81% +5 more

8 metrics

Named defendants 10 defendants First Amended Complaint

Failed-to-deliver shares 29.6 million shares Alleged in the amended complaint

Outstanding-share failures More than 81% Alleged failures to deliver

Single-session volume 554,032,865 shares March 17, 2026 trading session

Volume-to-shares ratio 15.3 times Company's then total issued shares on March 17, 2026

Shares available to borrow Zero shares Institutional lending market on March 17, 2026

Annualized borrow rate 621.45% March 17, 2026, up from 49.5% four days earlier

Earlier volume ratio 7.25 times Total issued shares on November 5, 2025

Historical Context

5 past events · Latest: Jun 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	CEO shareholder letter	Positive	+40.6%	Reported defense contract, platform progress, litigation activity, and Nasdaq compliance.
May 28	AI discovery partnership	Positive	+16.0%	Launched foundation-funded collaboration targeting Parkinson's disease and rare genetic epilepsies.
May 22	Expedited discovery order	Neutral	-2.6%	Federal judge ordered discovery to identify alleged naked short-selling defendants.
May 20	Reverse stock split	Negative	-10.2%	Announced a 1-for-8 reverse split to address Nasdaq minimum bid-price compliance.
May 04	Preferred issuance acquisition	Positive	+1.5%	Completed a $20.0 million preferred issuance to acquire neurotherapeutic intellectual property.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across the five selected events, four reactions matched the event tone and one procedural event diverged.

Key Terms

regulation sho, failures to deliver, rule 10b-5, rico statute

4 terms

regulation sho regulatory

"required under the federal law known as Regulation SHO"

Regulation SHO is a set of securities rules that govern short selling by requiring brokers to confirm they can borrow shares before letting someone sell them short, to close out unexplained failures to deliver shares, and to flag stocks with persistent delivery problems. It matters to investors because it helps prevent abusive trading that can distort prices and create artificial shortages, so it affects share availability, short-interest data, liquidity and potential price swings — like rules that stop people from lending out books they haven't actually borrowed.

failures to deliver financial

"resulting in what the Complaint asserts are widespread failures to deliver"

A failure to deliver occurs when a seller does not deliver the shares or securities they sold by the required settlement date, leaving the buyer unpaid or without the stock. It matters to investors because persistent or large failures can signal settlement breakdowns, stock borrowing shortages, or unusual selling activity—similar to a buyer paying for goods that never arrive—and can increase short-term price volatility and regulatory scrutiny.

rule 10b-5 regulatory

"under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5"

A U.S. securities rule that makes it illegal to lie, omit important facts, or use deceptive practices when buying or selling stocks and other securities. Think of it as a sports referee rule that keeps the playing field fair: investors rely on truthful information to decide whether to buy or sell, and violations can lead to lawsuits, fines, or forced returns of profits, which can affect a company’s stock price and investor confidence.

rico statute regulatory

"civil racketeering under the federal RICO statute"

A RICO statute is a law that lets prosecutors and private parties treat an organization as responsible when it carries out a pattern of related illegal activities—such as fraud, bribery, or extortion—so the group, not just individual actors, can be sued or prosecuted. For investors it matters because RICO claims can lead to criminal charges, large civil damages, asset seizures and reputational harm, risks that can rapidly destroy shareholder value and complicate deals or financing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Amended Complaint Alleges 29.6 Million Failed to Deliver Shares and Single Day Trading Volume of 15.3 Times Shares Outstanding, Company Seeks Treble Damages Under Federal RICO Statute

WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI), an AI driven precision medicine and biodefense company, today announced the filing of its First Amended Complaint in the United States District Court for the District of Delaware naming ten defendants, including three FINRA registered broker dealers, in connection with an alleged coordinated naked short selling scheme that the Company says generated failures to deliver on more than 81% of its outstanding shares. The Complaint makes clear that Lunai intends to add defendants who participated in the scheme upon confirming their identities through active continuing discovery and comprehensive mining of trading data and seeks a wider timeline of actively.

According to the Complaint, the named defendants and others sold short Lunai shares without borrowing or arranging to borrow the underlying securities as required under the federal law known as Regulation SHO, resulting in what the Complaint asserts are widespread failures to deliver, to enable what would otherwise be lawful short selling, during the period from November 2025 through May 2026. The Complaint alleges, using March 17, 2026, as an example, that 554,032,865 shares of LNAI traded in a single session, representing 15.3 times the Company's then total number of issued shares, on a date on which independent market data confirmed there were zero LNAI shares available to borrow in the institutional lending market, with the annualized borrow rate reaching 621.45%, up from 49.5% four days earlier. Previously, on the first day of the scheme to defraud as presently alleged, on November 5, 2025, the volume in that trading session reached 7.25 times the total number of the Company's then issued shares.

"The magnitude of this fraud is staggering – investors have lost real money, and it now is time for the fraudulent naked short sellers to be held responsible," said Jacob Frenkel, co-lead counsel and Chair of the Securities Enforcement and Government Investigations Practice at Dickinson Wright PLLC. "Conduct of this nature underscores why investor protection is such a critical mandate. Having served in the SEC's Enforcement Division and as a federal prosecutor, I would have found deeply gratifying pursuing such facts in my prior roles. I now am privileged to be on the side of a Company that has stepped forward to protect its business, its shareholders, and the integrity of its operations."

"These filings mark real progress in our effort to hold accountable the parties who profited from illegally shorting our stock," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our investigation identified failures to deliver equal to more than 80% of our outstanding shares and single day trading volumes many multiples of our entire share count. We intend to pursue full accountability, including treble damages under the federal racketeering statute, and we will continue to name additional participants in this scheme as our investigation identifies them. Our review does not stop at the dates in this complaint. We are watching current trading in LNAI in real time, and our forensic analysis reaches backward as well, so anyone who engaged in illegal naked short selling of our stock, before this window or since, should expect to be found and named."

The amended complaint asserts claims for securities fraud under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, market manipulation under Section 9(a) of the Exchange Act, civil conspiracy to defraud predicated on wire fraud, civil racketeering under the federal RICO statute, common law fraud, and tortious interference with contract arising from the Company's Nasdaq listing agreement. Lunai is seeking compensatory and special damages, treble damages under the RICO statute, injunctive relief, prejudgment and post judgment interest, costs, and attorneys' fees, and has demanded a jury trial.

Lunai is represented in this matter by Fox Rothschild LLP as Delaware counsel and Dickinson Wright PLLC as principal corporate and litigation counsel. The Company said its investigation into the trading activity described in the Complaint is ongoing, and it expects to amend the complaint further to additional participants as defendants. The claims and characterizations described in this release reflect allegations set forth in the Company's First Amended Complaint, which remain to be proven in court.

A copy of the First Amended Complaint is available at https://www.dickinson-wright.com/news-alerts/frenkel-dickinson-wright-lunai-lawsuit.

About Lunai Bioworks, Inc.

Lunai Bioworks, Inc. (Nasdaq: LNAI) is a Delaware corporation headquartered in Sacramento, California. Lunai is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company has developed a cancer immunotherapy for solid tumors and proprietary, patented technologies that transform complex biomedical data into predictive insights. Lunai's platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts in support of national security and biodefense applications through its AI platform. For more information, visit www.biosymetrics.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lunai's litigation strategy, the anticipated identification and naming of additional defendants, the potential outcome or recovery in the litigation described herein, and the Company's Nasdaq listing compliance. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the inherent uncertainty of litigation outcomes, the possibility that the Company will not prevail on some or all of its claims, the time and expense required to pursue the litigation, and other risks described in the Company's filings with the Securities and Exchange Commission. Lunai undertakes no obligation to update these forward looking statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-names-10-defendants-in-naked-short-selling-fraud-suit-302842515.html

SOURCE Lunai Bioworks Inc.